YPYoav D. Piura

Yoav D. Piura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoav D. Piura has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Performance of Diagnostic Criteria for Autoimmune Encephalitis in Patients With Suspected Rapidly Progressive Dementia

    by Yoav D. Piura, Anas Elgenidi, Philip W. Tipton, Nihal Satyadev, Neill R. Graff-Radford, Gregory S. Day

  • Clinical Factors Associated With Discordant Plasma P-Tau217 and Established Alzheimer Disease Biomarkers

    by Dror Shir, Alicia Algeciras-Schimnich, Yoav D. Piura, Joshua A. Bornhorst, Daniel J. Figdore, Anas Elgenidi, Christian Lachner, Neill R. Graff-Radford, Gregory S. Day

    Background and ObjectivesPlasma phosphorylated tau (p-tau) 217 is increasingly used for Alzheimer disease (AD) diagnosis and treatment decisions but may be discordant with established AD biomarkers...

  • Open Access

    Optimized plasma p‐tau217 and p‐tau217/Aβ42 cutoffs enhance detection of pre‐clinical Alzheimer's disease across diverse participants

    by Yoav D Piura, Paula A Aduen, Leah Schecter, Manoj K Jain, Alicia Algeciras‐Schimnich, Daniel J Figdore, Joshua Bornhorst, Ronald C Petersen, Clifford R Jack Jr, Neill R Graff‐Radford, et al.

    INTRODUCTION: Plasma p‐tau217 and p‐tau217/Aβ42 reliably identify non‐Hispanic White individuals with symptomatic and pre‐clinical AD. However, performance across ethnoracially diverse groups remains unknown. METHODS: Cognitively normal Black, Hispanic, and non‐Hispanic White participants completed cognitive evaluations, brain magnetic resonance imaging (MRI), amyloid and tau positron emission tomography (PET), and measures of kidney function. Plasma p‐tau217 and Aβ42 were measured using Fujirebio Lumipulse assays. Pre‐clinical AD detection was evaluated using symptomatic and cohort‐derived optimized cutoffs. RESULTS: Among 191 participants (57 Black, 46 Hispanic White, 88 non‐Hispanic White), age‐adjusted plasma p‐tau217 and p‐tau217/Aβ42 performed similarly in detecting amyloid‐positive individuals (≥ 25 Centiloids), regardless of race/ethnicity. Both measures independently correlated with amyloid deposition, whereas estimated glomerular filtration rate (eGFR) correlated solely with p‐tau217. Pre‐clinical AD optimized cutoffs (p‐tau217 ≥ 0.132 pg/ml; p‐tau217/Aβ42 ≥ 0.0059) outperformed cutoffs established in symptomatic individuals (sensitivity: 83% vs. 57%; 77% vs. 63%; negative predictive value [NPV] > 93%). DISCUSSION: Plasma biomarkers performed similarly across ethnoracially diverse cohorts. Optimized cutoffs may improve early detection and trial enrollment.


  • Open Access

    Autoimmune Encephalitis as Treatment-Responsive Cause of Rapidly Progressive Dementia

    by Robin W. van Steenhoven, Anna E.M. Bastiaansen, Jeroen Kerstens, Yvette S. Crijnen, Tessa Brand, Juliette Brenner, Tessa M. Bienfait, Juna M. de Vries, Yoav D. Piura, Nihal Satyadev, et al.

    Early recognition of patients with rapidly progressive dementia (RPD) attributed to autoimmune encephalitis (AE) is important because rapid initiation of immunotherapy improves outcomes. However, ancillary testing is often time-consuming because of the broad differential diagnosis, highlighting the need for accurate patient selection based on early clinical features. We aim to determine the frequency of AE subtypes in patients with RPD (AE-RPD) and characterize presenting subphenotypes (i.e., symptoms in addition to dementia) compared with other diagnoses. This prospective multicenter observational cohort study was conducted from December 2019 to December 2024 across centers in the Netherlands and included adult patients with RPD, defined as dementia beginning within 1 year of symptom onset. Clinical features and ancillary testing data were collected and reviewed by 3 neurologists. Serum and CSF were evaluated for neuronal/glial autoantibodies. A total of 147 patients were included (46% female; median age 67 years, range 36-86). AE-RPD was the largest diagnostic category (58/147; 39%) and most common treatment-responsive cause of RPD (58/95; 61%). Neurodegenerative diseases (20/147; 14%) and Creutzfeldt-Jakob disease (CJD, 17/147; 12%) accounted for the largest nonresponsive causes of RPD. RPD accompanied by seizures at first presentation was more frequent in AE-RPD compared with other diagnoses (20/58; 34% vs 9/89; 10%; p < 0.001), with anti-LG1 (11/20; 55%) encephalitis representing the most frequent underlying subtype. Seizures manifested as subtle focal events in 9 of 20 patients with AE-RPD (42%), complicating early clinical identification. Movement disorders were observed at presentation in similar proportions of patients with AE-RPD (17%) and CJD (35%; p = 0.11) but were more likely to emerge within 3 months of symptom onset in patients with RPD-AE (80% vs 25%; p = 0.004). In patients with AE-RPD without seizures, autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy was the most common subtype (8/31; 26%), mostly presenting with prominent psychotic features or movement disorders (both 4/8; 50%). In this study, AE was the most common treatment-responsive cause of RPD. Anti-leucine-rich, glioma-inactivated 1 encephalitis and autoimmune GFAP astrocytopathy were the predominant subtypes in AE-RPD.


  • Top Cited Papers

    Standardizing “Rapid”

    by Nihal Satyadev, Yoav D. Piura, Philip W. Tipton, S. Richard Dunham, John C. Morris, Michael D. Geschwind, Matthew Brier, Neill R. Graff-Radford, Gregory S. Day

    Rapidly progressive dementia (RPD) accounts for 3%-4% of dementia cases yet presents a disproportionate clinical challenge given the wide differential diagnosis and the need to quickly identify potentially treatment-responsive causes. The lack of a standardized definition of RPD challenges generalization of published findings and precludes multisite studies. We sought to determine whether a standardized definition, based on the Clinical Dementia Rating (CDR), could reliably distinguish individuals with a broad spectrum of causes of RPD early in the symptomatic course. RPD was defined as dementia (global CDR ≥1) developing within 1 year or incapacitation (global CDR ≥2) within 2 years of symptom onset. Patients with suspected RPD were referred from inpatient and outpatient settings at Mayo Clinic in Florida (Jacksonville, FL) and Washington University in St. Louis (Saint Louis, MO) and prospectively evaluated (RaPID cohort). Retrospective data from participants assessed across 46 research centers were also analyzed (National Alzheimer's Coordinating Center [NACC] data set). Characteristics and rates of progression (main outcome) were compared between typically progressive and RPD. Univariable and multivariable analyses were performed using Mann-Whitney U/Kruskal-Wallis (continuous) and Fisher exact/χ2 tests (binary), respectively. Our definition of RPD was compared against definitions identified through a scoping review conducted using a validated 6-stage approach. In the RaPID cohort, 185 of 248 (74.6%) patients met our CDR-based RPD definition (median [range] age-at-symptom onset: 68.8 years [22.0-90.7]; 45.4% female). Autoimmune (55/185, 29.7%), neurodegenerative (51/185, 27.6%), and prion diseases (35/185, 18.9%) predominated. Among 20,418 NACC participants with cognitive impairment, 836 (4.1%) met our RPD definition (median [range] age-at-symptom onset: 74 years [24-103]; 57.1% female). Neurodegenerative diseases predominated, especially Alzheimer disease (485/836, 58.0%). Individuals with RPD declined substantially faster (ΔCDR sum-of-boxes/year: RaPID, 14.4 ± 5.3 vs 4.3 ± 4.3, p < 0.001; NACC, 6.7 ± 3.1 vs 1.7 ± 1.4, p < 0.001). Our scoping review identified 22 studies that applied 10 distinct definitions of RPD. Uniquely, our CDR-based definition clearly distinguished individuals with a broad spectrum of causes of RPD, assessed across multiple sites/settings, supporting early diagnosis with minimal resource requirements. The CDR-based definition of RPD effectively identified individuals with a broad spectrum of causes of RPD early in the symptomatic course. The need for training and time to reliably administer the CDR may limit application of the proposed definition of RPD. Validation in additional cohorts is required to support generalizability.


  • Decoding the Clinical Features that Associate with Progression, Causes, and Outcomes in Patients with Suspected Rapidly Progressive Dementia

    by Yoav D. Piura, Nihal Satyadev, Nick Corriveau‐Lecavalier, Lindsey A. Kuchenbecker, Lauren E. Haydu, Michael D. Geschwind, Philip W. Tipton, Neill R. Graff‐Radford, Gregory S. Day

    Objective: To determine the clinical features that identify patients with suspected rapidly progressive dementia (RPD) who will develop RPD. Methods: Patients with suspected RPD were enrolled and followed at Mayo Clinic (Jacksonville, FL; January 2020 to October 2023) and Washington University (Saint Louis, MO; June 2016 to December 2019). Two dementia specialists independently reviewed clinical data and assigned diagnoses. Patients were diagnosed with RPD if they developed dementia within 1 year or incapacitation within 2 years of symptom onset. The associations between clinical features and causes and outcomes were explored via univariate and multivariate comparisons. Results: Of 248 patients with suspected RPD, 185 (74.6%) met criteria for RPD. Patients with RPD were older (62.6 ± 14.5 vs 55.2 ± 18.1 years; p < 0.001), and more frequently diagnosed with Alzheimer's disease or related dementias (OR 3.13, 95% CI 1.40, 7.31) or Creutzfeldt–Jakob disease (OR 4.67, 95% CI 1.38, 15.75). Visual agnosia (15/183; 8.2%), substantial brain atrophy (27/182; 14.8%), and periodic epileptiform discharges (11/151; 7.3%) were exclusively detected in patients with RPD. After controlling for age, intensive care unit admission (OR 4.77, 95% CI 1.61, 14.12), lack of seizures (OR 2.47, 95% CI 1.15, 5.31), abnormal brain magnetic resonance imaging (OR 2.01, 95% CI 0.997, 4.05), and cerebrospinal fluid white blood cell count ≤5 cells/mm 3 (OR 3.30, 95% CI 1.60, 6.82) were also independently associated with RPD. Patients with RPD were more likely to die or develop severe dementia (mean time to outcome, 36.1 months; 95% CI 31.2–41.0). Interpretation: Selected clinical features may identify patients with suspected RPD who are likely to continue to decline. Early recognition of these features may improve diagnostic accuracy and inform prognosis. ANN NEUROL 2025;98:764–776


  • Olfactory function in Susac syndrome

    by Yoav Piura, Arnon Karni, Hadar Kolb, Ifat Vigiser, Keren Regev


  • Open Access

    Long-term cognitive outcomes in Susac syndrome

    by Yoav Piura, Noa Bregman, Gitit Kave', Arnon Karni, Hadar Kolb, Ifat Vigiser, Tamara Shiner, Keren Regev

    Background Susac syndrome (SuS) is a rare autoimmune disorder mediated by the occlusion of micro-blood vessels in the brain, retina, and inner ear. Approximately 15% of cases present with the classic triad of CNS dysfunction, visual disturbances, and sensorineural hearing loss. While the literature is abundant about the severe, acute encephalopathy of SuS, not much is known about the extent of cognitive sequela in the post-era of efficient immunomodulatory treatment. Methods We report global cognitive function using a battery of cognitive tests in ten recovering SuS patients with an average of 2.9 (SD = 1.41) years post-disease onset. Results Patients showed intact delayed memory (both verbal and non-verbal) but below-average scores on tests of executive functions, and deficits in attention and copying. Results are discussed in light of the initial severity and extent of corpus callosum involvement on brain MRI. Conclusions study results suggest that the main cognitive sequela of SuS involves deficits in visual attention and executive functions possibly due to Corpus Callosum involvement. Additionally, this report supports a favorable prognosis for patients with SuS who receive a fast and efficacious immunomodulatory treatment protocol suggested in 2018.

  • CTGF/CCN2 has a possible detrimental role in the inflammation and the remyelination failure in the early stages of multiple sclerosis

    by Lior Fuchs, Karin Mausner-Fainberg, Anna Luban, Susanna Eva Asseyer, Maya Golan, Moshe Benhamou, Ilan Volovitz, Keren Regev, Ifat Vigiser, Yoav Piura, et al.


  • Neurosyphilis presenting as cranial nerve palsy, an entity which is easy to miss

    by Yoav Piura, Yair Mina, Orna Aizenstein, Avi Gadoth

    Neurosyphilis is a rare disease that until the 2000s was almost eradicated due to population awareness of HIV and efficient treatment. Since then, the prevalence of the entity is rising due to risk-associated behaviour such as unprotected intercourse. Neurosyphilis is still a difficult entity to diagnose especially when combined with acute HIV infection which can influence the usual clinical course of disease. In rare occasions, both acute HIV and early syphilis infection can present as mono or multiple cranial nerve palsies. This case demonstrates a rare manifestation of misdiagnosed early syphilis infection combined with acute HIV infection in a 34-year-old man with prior history of unprotected sex with men.